Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

teva pharma ag - temozolomidum, ammonii hydroxidum - capsule - temozolomidum 5 mg, lactosum 87.3 mg, carboxymethylamylum natricum a corresp. natrium 0.21 mg, silica colloidalis anhydrica, acidum tartaricum, acidum stearicum, kapselhülle: gelatina, e 171, drucktinte: lacca, propylenglycolum, ammonii hydroxidum, e 171, e 172 (flavum), e 132, pro capsula. - farmaco - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

teva pharma ag - temozolomidum, ammonii hydroxidum - capsule - temozolomidum 20 mg, lactosum 72.3 mg, carboxymethylamylum natricum a corresp. natrium 0.21 mg, silica colloidalis anhydrica, acidum tartaricum, acidum stearicum, kapselhülle: gelatina, e 171, drucktinte: lacca, propylenglycolum, ammonii hydroxidum, e 171, e 110, pro capsula. - farmaco - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

teva pharma ag - temozolomidum, ammonii hydroxidum - capsule - temozolomidum 100 mg, lactosum 83.6 mg, carboxymethylamylum natricum a corresp. natrium 0.42 mg, silica colloidalis anhydrica, acidum tartaricum, acidum stearicum, kapselhülle: gelatina, e 171, drucktinte: lacca, propylenglycolum, ammonii hydroxidum, kalii hydroxidum, e 172 (rubrum), e 172 (flavum), e 171, pro capsula. - farmaco - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

teva pharma ag - temozolomidum, ammonii hydroxidum - capsule - temozolomidum 140 mg, lactosum 117.04 mg, carboxymethylamylum natricum a corresp. natrium 0.588 mg, silica colloidalis anhydrica, acidum tartaricum, acidum stearicum, kapselhülle: gelatina, e 171, drucktinte: lacca, propylenglycolum, ammonii hydroxidum, e 132, pro capsula. - farmaco - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

teva pharma ag - temozolomidum, ammonii hydroxidum - capsule - temozolomidum 180 mg, lactosum 150.48 mg, carboxymethylamylum natricum a corresp. natrium 0.756 mg, silica colloidalis anhydrica, acidum tartaricum, acidum stearicum, kapselhülle: gelatina, e 171, drucktinte: lacca, propylenglycolum, ammonii hydroxidum, kalii hydroxidum, e 172 (rubrum), pro capsula. - farmaco - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

teva pharma ag - temozolomidum - capsule - temozolomidum 250 mg, lactosum 209 mg, carboxymethylamylum natricum a corresp. natrium 1.05 mg, silica colloidalis anhydrica, acidum tartaricum, acidum stearicum, kapselhülle: gelatina, e 171, drucktinte: lacca, propylenglycolum, ammonii hydroxidum, e 172 (nigrum), pro capsula. - farmaco - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - nepafenacum - augentropfensuspension - nepafenacum 3 mg, benzalkonii chloridum 0.05 mg, carmellosum natricum, guari gummi, carbomerum 974p, acidum boricum, dinatrii edetas, propylenglycolum, natrii chloridum, natrii hydroxidum aut acidum hydrochloridum ad ph, aqua purificata q.s. ad suspensionem pro 1 ml. - non steroidaler anti-infiammatori per l'applicazione sugli occhi - synthetika

Unione Europea - italiano - EMA (European Medicines Agency)

dipharma arzneimittel gmbh - sapropterin dicloridrato - phenylketonurias - altro apparato digerente e metabolismo prodotti, - sapropterin dipharma is indicated for the treatment of hyperphenylalaninaemia (hpa) in adults and paediatric patients of all ages with phenylketonuria (pku) who have been shown to be responsive to such treatment. sapropterin dipharma is also indicated for the treatment of hyperphenylalaninaemia (hpa) in adults and paediatric patients of all ages with tetrahydrobiopterin (bh4) deficiency who have been shown to be responsive to such treatment.

Unione Europea - italiano - EMA (European Medicines Agency)

novartis europharm limited - nepafenac - pain, postoperative; ophthalmologic surgical procedures - oftalmologici - nevanac is indicated for: , prevention and treatment of postoperative pain and inflammation associated with cataract surgery;, reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients.

Unione Europea - italiano - EMA (European Medicines Agency)

moderna biotech spain, s.l. - single-stranded, 5’-capped messenger rna (mrna) produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaccini - spikevax is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax bivalent original/omicron ba. 1 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against covid-19. spikevax bivalent original/omicron ba. 4-5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older.  spikevax xbb. 5 is indicated for active immunisation to prevent covid 19 caused by sars-cov-2 in individuals 6 months of age and older. the use of this vaccine should be in accordance with official recommendations.